Summit and Akeso sharpen case for ivonescimab with new Western data

Data ReadoutivonescimabPositive

AI Analysis

Summary

Summit Therapeutics and Akeso have presented new Western data for ivonescimab to address concerns about translating efficacy to Western populations, though statistical significance has not been confirmed.

Outcome Details

New Western data presented; statistical significance not yet disclosed

Importance:5/10

Sentiment:

0.30

clinical_datapartnershipivonescimabWestern populationregulatory

Related Companies

$TBIO

Read the original article

Published by BioSpace on July 22, 2026 3:14 PM

Read Original